lundi 2 janvier 2017

Onco Actu du 2 janvier 2017

1. Biologie

Radical new view of ovarian cancer implicates a ‘neglected’ origin [STAT]

3.1 Tabac

Chantix (varenicline) and Zyban (bupropion): Drug Safety Communication - Mental Health Side Effects Revised [FDA]

FDA drops black box warning on Pfizer's anti-smoking drug [Reuters]

3.4.1 Chimioprévention - aspirine

Regular Aspirin Use May Reduce Risk for Pancreatic Cancer [AACR]

3.7 Alcool

Breast cancer warning over wine was worded poorly, says health chief [The Guardian]

4.12 Biopsies liquides

Circulating tumour DNA technology: the future of cancer management? [PHG]

Searching for a blood test to monitor ovarian cancer [Cancer Research UK]

Blood test which tells pancreatic cancer patients how long they have left to live, developed by scientists [The Telegraph]

Tumor DNA in Blood May Serve as Prognostic Marker of Pancreatic Cancer [AACR]

4.13 Dép., diag. & prono. - Peau

A Serum Biomarker May Predict Response to Immunotherapy Drugs That Target Immune Checkpoints [AACR]

4.9 Dép., diag. & prono. - Sein

New Genetic Biomarker Identifies Patients With Increased Risk for Heart Damage Caused by Anthracycline Chemotherapy [AACR]

5. Traitements

Some glioblastoma patients benefit from ‘ineffective’ treatment [Stanford Medicine]

Study potentially explains vulnerability of young cancer patients to treatment toxicities

New laser therapy for low-risk prostate cancer shows promise [NHS Choices]

Early-phase trial demonstrates shrinkage in pediatric neural tumors [NCI]

Prostate cancer laser treatment could be a game changer for men [The Guardian]

5.10 Traitements - Essais

In Cancer Trials, a Lopsided Shot at Hope for Minorities [NY Times]

5.12 Immunothérapies

Vaccine ‘nanodiscs’ could personalize cancer immunotherapy [FierceBiotech]

Cancer-Free: One Recovery Inspires Another — and Could Help Thousands [NY Times]

Innate Pharma woos Mondher Mahjoubi away from AstraZeneca’s cancer research ops to take the helm [EndPoints]

Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits [NY Times]

5.12.1 Immunothérapies - partenariats

Medigene eyeing more immunotherapy deals after Bluebird pact [Reuters]

5.12.2 Immunothérapies - CAR-T

Juno Therapeutics’ and Celgene Corporation’s Investigational Drug JCAR017 Granted Breakthrough Therapy Designation from FDA and Priority Medicines Eligibility from EMA for Relapsed/Refractory Diffuse Large B-cell Lymphoma [Juno]

CAR-T therapy makes early inroads in treating brain cancer [STAT]

Kite Pharma Announces Successful Defense of Roberts Patent and Intent to Appeal U.S. Patent and Trademark Office Decision on a Narrow Patent Focused on Select CD28 CAR-T Products [Kite]

Juno Therapeutics Defeats Kite Pharma’s Challenge to CAR T-Cell Patent [Juno]

5.2 Pharma

Tesaro bags priority review, June PDUFA date for PARP inhibitor [FierceBiotech]

FDA Accepts Supplemental New Drug Application for Pfizer’s IBRANCE® (palbociclib) in HR+, HER2- Metastatic Breast Cancer [Pfizer]

Merrimack shutters a failing PhII breast cancer study for MM-302 [EndPoints]

AstraZeneca oncology head jumps ship to become Innate CEO [Reuters]

Seattle Genetics' cancer drug put on clinical hold after four deaths [Reuters]

5.2.1 Pharma - Partenariats

Bristol-Myers doubles down on PsiOxus in $936M-plus “armed” oncolytic virus deal [EndPoints]

In a first, AstraZeneca gains rights to an antisense KRAS drug in $165M Ionis deal [EndPoints]

5.2.2 Pharma - Fusions & Acquisitions

Sumitomo Dainippon beefs up oncology pipeline with $780M Tolero buyout [EndPoints]

5.2.3 Pharma - économie

Pharma's Pricing Troubles Will Get Worse in 2017 [Bloomberg]

5.3 Traitements - FDA, EMA, NICE...

E.U. Agency in Limbo as Hidden Costs of ‘Brexit’ Continue to Mount [NY Times]

US drug approvals plummet in 2016 [Nature]

FDA: For Hospitals that Significantly Violated Federal Adverse Event Reporting Requirement, No Additional Action Necessary [The Cancer Letter]

FDA Finds Lapses in Reporting of Patient Harm, Deaths Resulting from Medical Devices in Hospitals Nationwide [The Cancer Letter]

5.3.4 Traitements - AMM (FDA, EMA)

After an R&D odyssey filled with setbacks, Clovis wins an FDA OK for rucaparib [EndPoints]

Clovis Oncology Announces FDA Accelerated Approval of Rubraca™ (Rucaparib) for the Monotherapy Treatment of Advanced Ovarian Cancer in Women with Deleterious Germinale of Somatic BRCA Mutations Treated with Two of More Chemotherapies [Clovis]

Another Notch For “PARP” Blockers As FDA Approves Clovis Cancer Drug [Xconomy]

FDA grants accelerated approval to new treatment for advanced ovarian cancer [FDA]

Clovis's ovarian cancer drug wins accelerated FDA approval [Reuters]

KEYTRUDA® (pembrolizumab) Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express High Levels of PD-L1 [Merck]

European Medicines Agency’s CHMP Recommends Merck’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations [Merck]

CHMP recommends EU conditional approval of Roche’s Alecensa (alectinib) for people with previously treated ALK-positive NSCLC [Roche]

5.4 Traitements - Economie

NICE says liver cancer treatment to stay within the Cancer Drugs Fund, but not recommended for routine NHS use. [NICE]

Kadcyla too expensive for routine funding on NHS [NICE]

Germany’s Model For Drug Price Regulation Could Work In The US [Health Affairs Blog]

Japan to step up drug price reviews in bid to curb healthcare costs [Reuters]

Breast cancer drug rejected for NHS use on cost-benefit grounds [The Guardian]

6.1 Observation

The cancer registry is saving lives, but you’ve probably never heard of it [Cancer Research UK]

Cancer deaths will drop by 400,000 in next 20 years [Cancer Research UK]

U.S. melanoma rates keep rising [Reuters]

Many women get double mastectomy when only one breast has tumors [Reuters]

Older women with breast cancer still left out of medical trials [Reuters]

UK cancer death rates to fall by 15% by 2035 due to advances in research [The Guardian]

6.10.1 Politiques (USA)

Biden to Create Moonshot Institute Independent of Cancer Centers [The Cancer Letter]

6.5 Médecines alternatives

How cute. Naturopathic oncologists are pretending that theirs is a real medical specialty. [Respectful Insolence]

6.6 Publications

Cancer researcher in Germany loses multiple papers after misconduct finding [Retraction Watch]

6.8 Communication

News releases exaggerate the results of scientific research — a new study shows why this should stop [HealthNewsReview]

6.9 Controverses

AA Gill’s death doesn’t mean the NHS is broken – or that private healthcare is superior [The Guardian]